Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 61

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 1
Chunk 61
---

     (6,254,607) 
     (6,254,607)
  
    Balances,
    March 31, 2024 
     29,609,814  
    $-  
    $23,335,319  
    $(20,318,749) 
    $3,016,570 

    Balances,
    December 31, 2024 
     29,762,671  
     -  
     31,239,895  
     (30,596,858) 
     643,037 
  
    Balances 
     29,762,671  
     -  
     31,239,895  
     (30,596,858) 
     643,037 

    Stock based
    compensation 
     -  
     -  
     1,375,686  
     -  
     1,375,686 
  
    Net
    loss 
     -  
     -  
     -  
     (2,179,828) 
     (2,179,828)
  
    Balances,
    March 31, 2025 
     29,762,671  
    $-  
    $32,615,580  
    $(32,776,686) 
    $(161,106)
  
    Balances 
     29,762,671  
    $-  
    $32,615,580  
    $(32,776,686) 
    $(161,106)

See notes to condensed unaudited financial statements

5

TELOMIR PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

    Three
    Months Ended March 31, 

    2025  
    2024 

    Cash flows
    from operating activities 

    Net
    loss 
    $(2,179,828) 
    $(6,254,607)

    Adjustments
    to reconcile net loss to net cash from operating activities 

    Amortization
    of debt issuance costs 
     -  
     4,338,543 

    Stock-based
    compensation expense 
     1,375,686  
     - 

    Change